{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:01:38Z","timestamp":1793977298062,"version":"4.8.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.amjcard.2020.04.052","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:47:14Z","timestamp":1589568434000},"page":"163-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effect of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on Plasma Ceramide Levels"],"prefix":"10.1016","volume":"128","author":[{"given":"Qian","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Svatikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Meeusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Kludtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.04.052_bib0001","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.atherosclerosis.2015.10.022","article-title":"Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study","volume":"243","author":"Cheng","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0002","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0003","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","article-title":"Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort","volume":"36","author":"Havulinna","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0004","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/ATVBAHA.118.311199","article-title":"Plasma ceramides a novel predictor of major adverse cardiovascular events after coronary angiography","volume":"38","author":"Meeusen","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0005","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1210\/jc.2013-2559","article-title":"Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency","volume":"99","author":"Tarasov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0006","doi-asserted-by":"crossref","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","article-title":"Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome","volume":"99","author":"Ng","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0007","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1152\/ajpendo.00134.2015","article-title":"Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans","volume":"309","author":"Bergman","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0008","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/ATVBAHA.118.311199","article-title":"Plasma ceramides: a novel predictor of major adverse cardiovascular events after coronary angiography","volume":"38","author":"Meeusen","year":"2018","journal-title":"Arterioscler Throm Vasc"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0011","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248417724868","article-title":"Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables","volume":"23","author":"Filippatos","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0013","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.04.052_bib0014","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Lp","year":"2010","journal-title":"Lancet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920304744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920304744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:34:41Z","timestamp":1757572481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920304744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"alternative-id":["S0002914920304744"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.04.052","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on Plasma Ceramide Levels","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}